Sign up

Deep Track Capital, LP

$6.8B assets · 66 holdings · Q2 2026 · Filed 14 AUG 2026

About Deep Track Capital, LP’s 13F portfolio

Deep Track Capital, LP is an institutional investment manager that discloses its US-listed holdings each quarter through an SEC Form 13F filing. As of , Deep Track Capital, LP reported $6.8B across 66 US-listed positions (). Its largest position is GUARDANT HEALTH INC (GH) at 7.5% of the reported book, and its ten biggest holdings make up 40% of the portfolio. Browse every manager in the fund managers directory, or see the legendary investors we track on the superinvestors page.

$6.8B
Assets (13F)
#662
of 8,839 by size
66
Holdings
40%
Top-10 weight
40
Buys
29
Sells
Top holdings · Q2 2026
66 total
#StockPrice% of portfolioSharesValue
1
NASDAQ: GH
GUARDANT HEALTH INC
$145.14
+1.30%
7.5%
3.4M$509.1M
2
NASDAQ: IMVT
IMMUNOVANT INC
$33.17
−0.12%
5.3%
9.3M$359.9M
3
NASDAQ: GPCR
STRUCTURE THERAPEUTICS INC
$17.36
−4.46%
3.7%
4.7M$254.4M
4
NASDAQ: PCVX
VAXCYTE INC
$58.52
−1.48%
3.7%
4.3M$250.0M
5
NASDAQ: ALNY
ALNYLAM PHARMACEUTICALS INC
$149.40
−4.54%
3.7%
825K$248.3M
6
NYSE: MANE
VERADERMICS INC
—
—
3.6%
2.0M$245.9M
7
NASDAQ: TARS
TARSUS PHARMACEUTICALS INC
$75.95
−2.88%
3.4%
3.7M$230.8M
8
NASDAQ: NUVL
NUVALENT INC
$123.96
0.00%
3.2%
1.8M$220.2M
9
NASDAQ: ALKS
ALKERMES PLC
$46.85
+3.08%
3.1%
4.0M$209.6M
10
NASDAQ: OCUL
OCULAR THERAPEUTIX INC
$5.94
−1.33%
2.8%
19.7M$193.3M
11
NASDAQ: BMRN
BIOMARIN PHARMACEUTICAL INC
$61.43
+4.99%
2.8%
3.3M$189.3M
12
NASDAQ: NRIX
NURIX THERAPEUTICS INC
$14.10
−0.98%
2.8%
7.7M$187.7M
13
NASDAQ: ORKA
ORUKA THERAPEUTICS INC
$95.74
−0.60%
2.7%
1.9M$183.3M
14
NASDAQ: ALMS
ALUMIS INC
$4.40
−9.19%
2.6%
6.3M$178.6M
15
NASDAQ: IONS
IONIS PHARMACEUTICALS INC
$27.39
+1.59%
2.6%
2.2M$174.4M
16
NASDAQ: CMPS
COMPASS PATHWAYS PLC
$8.12
+1.75%
2.5%
12.2M$172.1M
17
NASDAQ: VERA
VERA THERAPEUTICS INC
$25.58
−2.37%
2.5%
4.0M$171.6M
18
NASDAQ: AXSM
AXSOME THERAPEUTICS INC.
$134.00
−1.43%
2.5%
700K$171.3M
19
NASDAQ: GMAB
GENMAB A/S
$50.97
−1.91%
2.3%
5.7M$155.2M
20
NASDAQ: MLTX
MOONLAKE IMMUNOTHERAPEUTICS
$10.79
−4.09%
2.0%
7.0M$136.3M
21
NASDAQ: COAG
HEMAB THERAPEUTICS HLDGS INC
—
—
1.9%
3.6M$132.3M
22
NASDAQ: TNGX
TANGO THERAPEUTICS INC
$21.89
−1.00%
1.9%
4.2M$131.3M
23
NASDAQ: DFTX
DEFINIUM THERAPEUTICS INC
—
—
1.9%
2.8M$129.4M
24
NASDAQ: GRAL
GRAIL INC
$102.10
−3.57%
1.8%
1.8M$125.3M
25
NASDAQ: BCAX
BICARA THERAPEUTICS INC
$9.38
−2.29%
1.8%
4.1M$121.7M

Showing 1–25 of 66 positions on this page reported in this 13F.

Sector allocation
  • Healthcare92%
Recent activity · vs 2026-03-31
Bought40
  • AddedGHGUARDANT HEALTH INC+1.6%$509.1M
  • AddedGPCRSTRUCTURE THERAPEUTICS INC+10.8%$254.4M
  • NewALNYALNYLAM PHARMACEUTICALS INC—$248.3M
  • AddedMANEVERADERMICS INC+300%$245.9M
  • AddedTARSTARSUS PHARMACEUTICALS INC+1.9%$230.8M
  • AddedNUVLNUVALENT INC+29.6%$220.2M
  • AddedALKSALKERMES PLC+11.4%$209.6M
  • AddedBMRNBIOMARIN PHARMACEUTICAL INC+188%$189.3M
  • AddedNRIXNURIX THERAPEUTICS INC+21.9%$187.7M
  • AddedIONSIONIS PHARMACEUTICALS INC+12.8%$174.4M
Sold29
  • ReducedIMVTIMMUNOVANT INC−19.0%$359.9M
  • ReducedORKAORUKA THERAPEUTICS INC−5.3%$183.3M
  • ReducedALMSALUMIS INC−6.3%$178.6M
  • ReducedVERAVERA THERAPEUTICS INC−2.6%$171.6M
  • ReducedAXSMAXSOME THERAPEUTICS INC.−36.4%$171.3M
  • ReducedDFTXDEFINIUM THERAPEUTICS INC−8.3%$129.4M
  • ReducedMBXMBX BIOSCIENCES INC−37.2%$95.6M
  • ReducedCYTKCYTOKINETICS INC−49.1%$59.6M
  • ReducedDYNDYNE THERAPEUTICS INC−25.0%$33.3M
  • ReducedXFORX4 PHARMACEUTICALS INC−7.3%$27.5M
5%+ Beneficial Ownership Stakes · 10 passive (13G)

Companies where this manager has disclosed a stake of more than 5% of a class of shares, as reported to the SEC on Schedule 13D (activist) or 13G (passive). Figures are as disclosed in each filing — tap a date to open the source document.

#StockType% of classSharesFiled
1
TCXB
TCGX Acquisition Corp. II
13G9.9%990KFiled 23 OCT 2026
2
FLSC
Frazier Life Sciences Acquisition Corp. II
13G9.0%700KFiled 21 OCT 2026
3
COAG
Hemab Therapeutics Holdings, Inc.
13G8.2%3.6MFiled 08 MAY 2026
4
ATTO
Attovia Therapeutics, Inc.
13G7.5%3.2MFiled 12 AUG 2026
5
GPCR
Structure Therapeutics Inc.
13G7.2% · 2 classes15.0MFiled 16 NOV 2026
6
LTGO
Latigo Biotherapeutics, Inc.
13G7.0%4.4MFiled 13 AUG 2026
7
ENGN
enGene Holdings Inc.
13G6.7%4.3MFiled 18 NOV 2025
8
BCAX
Bicara Therapeutics Inc.
13G6.2% · 2 classes4.1MFiled 15 MAY 2026
9
JTTT
JATT III Acquisition Corp
13G5.8%450KFiled 02 SEP 2026
10
GERN
Geron Corp
13G5.1%32.5MFiled 13 FEB 2026

Showing all 10 disclosed stakes.

Reading Deep Track Capital, LP’s 13F portfolio

Deep Track Capital, LP’s $6.8B 13F book is spread across 66 reported positions and is concentrated toward its biggest ideas, with the top ten holdings at 40%. The largest positions carry real weight, so how those names perform matters a lot to the overall book. Its five largest positions are GH, IMVT, GPCR, PCVX and ALNY, led by GUARDANT HEALTH INC (GH) at 7.5% of the portfolio. The heaviest sector exposure is Healthcare (92%).

What Deep Track Capital, LP changed last quarter

Between 2026-03-31 and Q2 2026, Deep Track Capital, LP was a net buyer: it opened 18 new positions and added to 22 more, while trimming 15 and closing 14 outright. Against a 66-name book, that is high turnover, pointing to an active reshuffle of the book. Its largest new or increased position was GUARDANT HEALTH INC (GH), and its biggest reduction was IMMUNOVANT INC (IMVT).

What a 13F does and doesn’t reveal

A 13F captures only Deep Track Capital, LP’s long positions in US-listed stocks at a single quarter-end, so it is best read as a lagged snapshot rather than a live portfolio. It won’t show shorts, cash, bonds, or holdings listed outside the US, and it never reveals the price paid or the reasoning behind a trade. The signal is in the pattern over time: which names Deep Track Capital, LP is building up, trimming, or exiting, and how concentrated the book stays from quarter to quarter.

Frequently asked questions

What is an SEC 13F filing?

A Form 13F is a report that every institutional investment manager with at least $100 million in US-listed securities must file with the SEC within 45 days of each quarter's end. It lists the manager's long positions in US-listed stocks and certain options, with the share count and market value of each. Deep Track Capital, LP's profile on this page is built directly from those filings.

How current is the 13F data on Deep Track Capital, LP's page?

It reflects Deep Track Capital, LP's most recently filed 13F, currently the quarter ending Q2 2026. Because managers have up to 45 days after a quarter closes to file, a 13F is always a slightly lagged view rather than a live portfolio. When Deep Track Capital, LP files its next quarterly report, this page refreshes automatically.

Can I see Deep Track Capital, LP's complete list of holdings?

This page highlights Deep Track Capital, LP's largest positions rather than all 66 names in the filing. The complete, position-by-position 13F is public and available from the SEC's EDGAR database under Deep Track Capital, LP's filings.

Does a 13F show everything Deep Track Capital, LP owns?

No. A 13F only covers long positions in US-listed stocks and certain options. It leaves out short positions, cash, bonds, commodities, foreign-listed stocks, and private holdings, so it is a partial view of Deep Track Capital, LP's book rather than its full strategy or total assets.

Is 13F data investment advice?

No. Everything here is educational. 13F positions are disclosed with a delay, cover only long US-listed holdings, and never explain why Deep Track Capital, LP made a trade or at what price. Treat it as a research lens, not a recommendation, and speak with a licensed financial advisor before making investment decisions.

Not investment advice. Holdings data comes from public SEC Form 13F filings, which are filed with a delay of up to 45 days and may be amended later. It describes historical, disclosed positions in US-listed securities only, meaning no shorts, cash, or foreign holdings, and it is not a recommendation. Always do your own research and speak with a licensed financial advisor before making investment decisions.